

Wen-Chien Chou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8602027/publications.pdf>

Version: 2024-02-01

135
papers

6,678
citations

108046

37
h-index

75989

78
g-index

135
all docs

135
docs citations

135
times ranked

8657
citing authors

#	ARTICLE	IF	CITATIONS
1	Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission. <i>Bone Marrow Transplantation</i> , 2022, 57, 95-105.	1.3	8
2	Effectiveness of induction regimens on survival outcome in acute myeloid leukemia patients: a real-world data from 2001 to 2015. <i>Annals of Hematology</i> , 2022, 101, 109-118.	0.8	1
3	Polatuzumab vedotinâ€‘based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience. <i>Annals of Hematology</i> , 2022, 101, 349-358.	0.8	12
4	Oncogenesis induced by combined Phf6 and Idh2 mutations through increased oncometabolites and impaired DNA repair. <i>Oncogene</i> , 2022, 41, 1576-1588.	2.6	3
5	Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	23
6	The expression levels of long nonâ€‘coding RNA <i>KIAA0125</i> are associated with distinct clinical and biological features in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2021, 192, 589-598.	1.2	5
7	Distinct clinical and biological characteristics of acute myeloid leukemia with higher expression of long noncoding RNA KIAA0125. <i>Annals of Hematology</i> , 2021, 100, 487-498.	0.8	19
8	Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML. <i>Blood Advances</i> , 2021, 5, 2456-2466.	2.5	31
9	Bone marrow plasma level of decorin may be associated with improved treatment outcomes in a subset of multiple myeloma patients. <i>Journal of the Formosan Medical Association</i> , 2021, 121, 643-643.	0.8	1
10	Immune signatures of bone marrow cells can independently predict prognosis in patients with myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2021, , .	1.2	2
11	PDâ€‘1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients. <i>Journal of Pathology: Clinical Research</i> , 2021, , .	1.3	2
12	A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromes. <i>Blood Advances</i> , 2021, 5, 4535-4548.	2.5	19
13	<i>RUNX1</i> Expression Can be Complementary to <i>RUNX1</i> Mutation in MDS Prognostication. <i>Blood</i> , 2021, 138, 2614-2614.	0.6	0
14	Metabolic Profiling Reveals Cellular Reprogramming of Acute Myeloid Leukemia By Omipalisib through Serine Synthesis Pathway. <i>Blood</i> , 2021, 138, 3296-3296.	0.6	2
15	Epidemiology of Light-Chain Amyloidosis: A Population-Based Cohort Study in Taiwan. <i>Blood</i> , 2021, 138, 1637-1637.	0.6	3
16	Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed <i>FLT3</i> -Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy. <i>Blood</i> , 2021, 138, 700-700.	0.6	18
17	ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden. <i>Blood Cancer Journal</i> , 2020, 10, 99.	2.8	5
18	Knock-out of Hopx disrupts stemness and quiescence of hematopoietic stem cells in mice. <i>Oncogene</i> , 2020, 39, 5112-5123.	2.6	22

#	ARTICLE	IF	CITATIONS
19	Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. <i>Annals of Hematology</i> , 2020, 99, 501-511.	0.8	52
20	A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients. <i>Blood Advances</i> , 2020, 4, 644-654.	2.5	14
21	Accurate Prediction of Gene Mutations with Flow Cytometry Immune-Phenotyping By Machine Learning Algorithm. <i>Blood</i> , 2020, 136, 7-8.	0.6	2
22	Prognostic Prediction with Static-Dynamic Clinical and Pathological Parameters By Machine Learning Algorithm in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2020, 136, 1-1.	0.6	0
23	Risk Factors for Thrombotic Events in Patients with PNH: A Nested Case-Control Study in the International PNH Registry. <i>Blood</i> , 2020, 136, 6-8.	0.6	1
24	Comparative study on baseline clinical characteristics of Asian versus non-Asian patients with paroxysmal nocturnal hemoglobinuria. <i>International Journal of Hematology</i> , 2019, 110, 411-418.	0.7	9
25	Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. <i>New England Journal of Medicine</i> , 2019, 381, 1728-1740.	13.9	796
26	Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients. <i>EBioMedicine</i> , 2019, 40, 240-250.	2.7	23
27	Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome. <i>BMC Cancer</i> , 2019, 19, 617.	1.1	43
28	Adoptive donor immunity protects against resolved hepatitis B virus reactivation after allogeneic haematopoietic stem cell transplantation in the world's largest retrospective cohort study. <i>British Journal of Haematology</i> , 2019, 186, 72-85.	1.2	11
29	Phf6-null hematopoietic stem cells have enhanced self-renewal capacity and oncogenic potentials. <i>Blood Advances</i> , 2019, 3, 2355-2367.	2.5	30
30	Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. <i>Blood</i> , 2019, 133, 1140-1151.	0.6	96
31	Automatic Bone Marrow Cell Identification and Classification By Deep Neural Network. <i>Blood</i> , 2019, 134, 2084-2084.	0.6	20
32	The Clinical Association and Prognostic Impact of IL1RAP Expression in Patients with De Novo Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2705-2705.	0.6	0
33	Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome. <i>Blood Cancer Journal</i> , 2018, 8, 39.	2.8	68
34	Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor risk factor in de novo acute myeloid leukemia patients. <i>European Journal of Haematology</i> , 2018, 101, 86-94.	1.1	31
35	Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome. <i>Clinical Epigenetics</i> , 2018, 10, 42.	1.8	36
36	Clinically validated machine learning algorithm for detecting residual diseases with multicolor flow cytometry analysis in acute myeloid leukemia and myelodysplastic syndrome. <i>EBioMedicine</i> , 2018, 37, 91-100.	2.7	54

#	ARTICLE	IF	CITATIONS
37	GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2018, 8, 87.	2.8	34
38	Concomitant <i>WT1</i> mutations predict poor prognosis in acute myeloid leukemia patients with double mutant <i>CEBPA</i> . <i>Haematologica</i> , 2018, 103, e510-e513.	1.7	29
39	Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan. <i>BMC Gastroenterology</i> , 2018, 18, 6.	0.8	20
40	The prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome. <i>Blood Cancer Journal</i> , 2018, 8, 78.	2.8	23
41	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1363-1374.	1.4	20
42	Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Standard Chemoimmunotherapy. <i>Blood</i> , 2018, 132, 4235-4235.	0.6	0
43	Aurora A and NF- κ B Survival Pathway Drive Chemoresistance in Acute Myeloid Leukemia via the TRAF-Interacting Protein TIFA. <i>Cancer Research</i> , 2017, 77, 494-508.	0.4	41
44	Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e430-e439.	0.7	4
45	Higher HOPX expression is associated with distinct clinical and biological features and predicts poor prognosis in <i>de novo</i> acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1044-1053.	1.7	35
46	Prognostic impacts and dynamic changes of cohesin complex gene mutations in <i>de novo</i> acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2017, 7, 663.	2.8	39
47	The distinct biological implications of <i>Asx1</i> mutation and its roles in leukemogenesis revealed by a knock-in mouse model. <i>Journal of Hematology and Oncology</i> , 2017, 10, 139.	6.9	40
48	A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes. <i>Blood Advances</i> , 2017, 1, 1505-1516.	2.5	19
49	Germline variations at <i>JAK2</i> , <i>TERT</i> , <i>HBS1L-MYB</i> and <i>MECOM</i> and the risk of myeloproliferative neoplasms in Taiwanese population. <i>Oncotarget</i> , 2017, 8, 76204-76213.	0.8	11
50	High expression of <i>dedicator of cytokinesis 1</i> (<i>DOCK1</i>) confers poor prognosis in acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 72250-72259.	0.8	20
51	A three-gene expression-based risk score can refine the European LeukemiaNet AML classification. <i>Journal of Hematology and Oncology</i> , 2016, 9, 78.	6.9	21
52	Reduced incidence of interstitial pneumonitis after allogeneic hematopoietic stem cell transplantation using a modified technique of total body irradiation. <i>Scientific Reports</i> , 2016, 6, 36730.	1.6	18
53	Characteristics of Taiwanese patients of PNH in the international PNH registry. <i>Thrombosis Journal</i> , 2016, 14, 39.	0.9	4
54	The Clinical and Biological Effects of the Expression of <i>Dedicator of Cytokinesis 1</i> (<i>DOCK1</i>) in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1695-1695.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS). <i>Oncotarget</i> , 2016, 7, 63177-63188.	0.8	21
56	Splicing factor mutations predict poor prognosis in patients with <i>de novo</i> acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 9084-9101.	0.8	77
57	Aberrant Patterns of Alternative Splicing Are Frequent Events and Harbor Prognostic Significance in Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 49-49.	0.6	0
58	The Clinical and Biological Effects of Expression of Dedicator of Cytokinesis 1 (DOCK1) in Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 5517-5517.	0.6	0
59	The Clinical Characteristics, Genetic Alterations and Prognostic Significance of De Novo Acute Myeloid Leukemia (AML) with Hyperleukocytosis (HL). <i>Blood</i> , 2016, 128, 2860-2860.	0.6	0
60	A 6-Lncrna Scoring System for Prognostication of Adult Myelodysplastic Syndromes. <i>Blood</i> , 2016, 128, 4344-4344.	0.6	0
61	Overexpression of Calr Mutants Perturbs Developmental Hematopoiesis in Zebrafish Embryos. <i>Blood</i> , 2016, 128, 4282-4282.	0.6	0
62	Clinical and Prognostic Implications of Roundabout 4 (Robo4) in Adult Patients with Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2015, 10, e0119831.	1.1	6
63	High Risk of Hepatitis B Reactivation among Patients with Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2015, 10, e0126037.	1.1	21
64	Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study. <i>PLoS ONE</i> , 2015, 10, e0137552.	1.1	7
65	Clinical characteristics and treatment outcomes of patients with candidaemia due to <i>Candida parapsilosis sensu lato</i> species at a medical centre in Taiwan, 2000-2012. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1531-1538.	1.3	21
66	GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution. <i>Annals of Hematology</i> , 2015, 94, 211-221.	0.8	23
67	High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan. <i>PLoS ONE</i> , 2015, 10, e0128410.	1.1	50
68	Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults. <i>BMC Cancer</i> , 2015, 15, 344.	1.1	48
69	Rapid and sensitive detection of CALR exon 9 mutations using high-resolution melting analysis. <i>Clinica Chimica Acta</i> , 2015, 440, 133-139.	0.5	19
70	An mRNA expression signature for prognostication in <i>de novo</i> acute myeloid leukemia patients with normal karyotype. <i>Oncotarget</i> , 2015, 6, 39098-39110.	0.8	42
71	The Clinical and Biological Characterization of De Novo Acute Myeloid Leukemia (AML) with GATA2 Mutation. <i>Blood</i> , 2015, 126, 3822-3822.	0.6	0
72	Genetic Alterations and Their Clinical Implications in Older Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 4956-4956.	0.6	0

#	ARTICLE	IF	CITATIONS
73	B Cell Immune Profiles in Essential Thrombocythemia with Calr Mutations: Clinical and Molecular Correlates. <i>Blood</i> , 2015, 126, 1610-1610.	0.6	0
74	IPSSâ€” in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better riskâ€”stratify the patients. <i>American Journal of Hematology</i> , 2014, 89, E142-9.	2.0	16
75	<i>IDH</i> mutations are closely associated with mutations of <i>DNMT3A</i>, <i>ASXL1</i> and <i>SRSF2</i> in patients with myelodysplastic syndromes and are stable during disease evolution. <i>American Journal of Hematology</i> , 2014, 89, 137-144.	2.0	76
76	Clinical implications of the <i>SETBP1</i> mutation in patients with primary myelodysplastic syndrome and its stability during disease progression. <i>American Journal of Hematology</i> , 2014, 89, 181-186.	2.0	56
77	Expression of cereblon protein assessed by immunohistochemical staining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. <i>Annals of Hematology</i> , 2014, 93, 1371-1380.	0.8	54
78	Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations. <i>Leukemia Research</i> , 2014, 38, 1278-1284.	0.4	22
79	<i>SF3B1</i> mutations in patients with myelodysplastic syndromes: The mutation is stable during disease evolution. <i>American Journal of Hematology</i> , 2014, 89, E109-15.	2.0	34
80	The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression. <i>Haematologica</i> , 2014, 99, 1799-1807.	1.7	13
81	A Simple, Powerful, and Widely Applicable Micro-RNA Scoring System in Prognostication of De Novo Myeloid Leukemia Patients. <i>Blood</i> , 2014, 124, 71-71.	0.6	1
82	Hierarchical cluster analysis of immunophenotype classify AML patients with NPM1 gene mutation into two groups with distinct prognosis. <i>BMC Cancer</i> , 2013, 13, 107.	1.1	11
83	Higher <i>lipocalin 2</i> expression may represent an independent favorable prognostic factor in cytogenetically normal acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1614-1625.	0.6	21
84	Chromosomal abnormalities by conventional cytogenetics and interphase fluorescence in situ hybridization in chronic lymphocytic leukemia in Taiwan, an area with low incidenceâ€”clinical implication and comparison between the West and the East. <i>Annals of Hematology</i> , 2013, 92, 799-806.	0.8	14
85	Clinical features of patients with infections caused by <i>Candida guilliermondii</i> and <i>Candida fermentati</i> and antifungal susceptibility of the isolates at a medical centre in Taiwan, 2001-10. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2632-2635.	1.3	24
86	Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression. <i>American Journal of Hematology</i> , 2013, 88, E277-82.	2.0	56
87	Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia. <i>Blood</i> , 2013, 121, 3172-3180.	0.6	58
88	Clinical and Microbiological Characteristics of Perianal Infections in Adult Patients with Acute Leukemia. <i>PLoS ONE</i> , 2013, 8, e60624.	1.1	48
89	Cfi-1 is the transcriptional repressor of <i>SOCS1</i> in acute myeloid leukemia cells. <i>Journal of Leukocyte Biology</i> , 2013, 95, 105-115.	1.5	17
90	The Role Of tet2 DNA Methylcytosine Dioxygenase In Zebrafish Early Hematopoiesis. <i>Blood</i> , 2013, 122, 1204-1204.	0.6	0

#	ARTICLE	IF	CITATIONS
91	The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. <i>Blood</i> , 2012, 120, 3106-3111.	0.6	127
92	Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 2670-2677.	0.8	998
93	Clinical characteristics of candidaemia in adults with haematological malignancy, and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2001-2010. <i>International Journal of Antimicrobial Agents</i> , 2012, 40, 533-538.	1.1	30
94	A Knock-In Npm1 Mutation in Mice Results in Myeloproliferation and Implies a Perturbation in Hematopoietic Microenvironment. <i>PLoS ONE</i> , 2012, 7, e49769.	1.1	21
95	DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. <i>Blood</i> , 2012, 119, 559-568.	0.6	211
96	Rapid Assessment of the Heterogeneous Methylation Status of CEBPA in Patients with Acute Myeloid Leukemia by Using High-Resolution Melting Profile. <i>Journal of Molecular Diagnostics</i> , 2011, 13, 514-519.	1.2	13
97	Genetic Alterations and Their Clinical Implications in Acute Myeloid Leukemia. , 2011, , .		1
98	The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. <i>Leukemia</i> , 2011, 25, 246-253.	3.3	150
99	TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. <i>Blood</i> , 2011, 118, 3803-3810.	0.6	272
100	Dynamic Contrast-enhanced MR Imaging Measurement of Vertebral Bone Marrow Perfusion May Be Indicator of Outcome of Acute Myeloid Leukemia Patients in Remission. <i>Radiology</i> , 2011, 258, 821-831.	3.6	44
101	DNMT3A Mutations in Acute Myeloid Leukemia-Stability During Disease Evolution and the Clinical Implication. <i>Blood</i> , 2011, 118, 409-409.	0.6	23
102	Quantitative Monitoring of EBV Viral Load in 222 Hematopoietic Stem Cell Transplant Patients: Risk Analysis and Development of EBV-Associated Post-Transplant Lymphoproliferative Diseases (PTLD). <i>Blood</i> , 2011, 118, 3018-3018.	0.6	0
103	A "canonical" Npm1 mutation Knock-in Mouse Model Revealed Subtle but Definitive Myeloid Expansion with Poor HSC Niche Interaction. <i>Blood</i> , 2011, 118, 762-762.	0.6	0
104	Changes in magnetic resonance bone marrow angiogenesis on day 7 after induction chemotherapy can predict outcome of acute myeloid leukemia. <i>Haematologica</i> , 2010, 95, 1420-1424.	1.7	17
105	Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. <i>Blood</i> , 2010, 115, 2749-2754.	0.6	193
106	WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. <i>Blood</i> , 2010, 115, 5222-5231.	0.6	156
107	A single-tube, sensitive multiplex method for screening of isocitrate dehydrogenase 1 (IDH1) mutations. <i>Blood</i> , 2010, 116, 495-496.	0.6	12
108	Psoas Abscess Caused by Non-Typhoid <i>Salmonella</i> in a Patient with Severe Aplastic Anemia. <i>Yonsei Medical Journal</i> , 2010, 51, 472.	0.9	4

#	ARTICLE	IF	CITATIONS
109	Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. <i>Blood</i> , 2010, 116, 4086-4094.	0.6	187
110	Bone Marrow Hypoplasia Induced by Conditional Knockout of the RNase III Domain of Dicer-1. <i>Blood</i> , 2010, 116, 2226-2226.	0.6	0
111	Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival. <i>Blood</i> , 2009, 113, 3161-3167.	0.6	75
112	AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. <i>Blood</i> , 2009, 114, 5352-5361.	0.6	318
113	AML1/RUNX1 Mutations in 470 Adult Patients with De Novo Acute Myeloid Leukemia: Prognostic Implication and Interaction with Other Gene Alterations.. <i>Blood</i> , 2009, 114, 1564-1564.	0.6	3
114	CEBPA Methylation as a Prognostic Biomarker in Adult Patients with De Novo AML.. <i>Blood</i> , 2009, 114, 1569-1569.	0.6	0
115	Role of Gene Mutations in Adult Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2009, 114, 3373-3373.	0.6	0
116	Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. <i>Leukemia Research</i> , 2008, 32, 904-912.	0.4	55
117	Marrow osteopontin level as a prognostic factor in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2008, 141, 736-739.	1.2	12
118	Clinical and Biological Characterization of Adult Patients with Acute Myeloid Leukemia Bearing T(7;11)(p15;p15)â€”Analysis of 536 Patients. <i>Blood</i> , 2008, 112, 2535-2535.	0.6	1
119	Hierarchical Cluster Analysis of Immunophenotype in AML Patients with NPM1 Gene Mutation Reveals Two Distinct Groups with Different Prognosis.. <i>Blood</i> , 2008, 112, 1495-1495.	0.6	0
120	Methylation Status of miRNA Let-7a-3 in Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 4482-4482.	0.6	0
121	Severe pulmonary complications after initial treatment with rituximab for the Asian-variant of intravascular lymphoma. <i>Haematologica</i> , 2007, 92, 141-142.	1.7	39
122	<i>RUNX1</i> gene mutation in primary myelodysplastic syndrome â€” the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. <i>British Journal of Haematology</i> , 2007, 139, 405-414.	1.2	122
123	Characterization of Acute Myeloid Leukemia with PTPN11 Mutation - The Mutation Is Closely Associated with NPM1 Mutation but Inversely Related to FLT3/ITD.. <i>Blood</i> , 2007, 110, 3490-3490.	0.6	2
124	Clinical implications of SOCS1 methylation in myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2006, 135, 317-323.	1.2	32
125	Nucleophosmin Mutations in De novo Acute Myeloid Leukemia: The Age-Dependent Incidences and the Stability during Disease Evolution. <i>Cancer Research</i> , 2006, 66, 3310-3316.	0.4	165
126	Quantitative Assessment of Minimal Residual Disease Predicts Outcome of Patients of Acute Myeloid Leukemia with Nucleophosmin (NPM) Mutation.. <i>Blood</i> , 2006, 108, 561-561.	0.6	6

#	ARTICLE	IF	CITATIONS
127	Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies. <i>Current Opinion in Hematology</i> , 2005, 12, 1-6.	1.2	74
128	Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. <i>Blood</i> , 2005, 106, 304-310.	0.6	74
129	Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 4578-4583.	3.3	207
130	Arsenic inhibition of telomerase transcription leads to genetic instability. <i>Journal of Clinical Investigation</i> , 2001, 108, 1541-1547.	3.9	101
131	Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 1998, 103, 1092-1095.	1.2	120
132	Clonal disease of natural killer large granular lymphocytes in Taiwan. <i>British Journal of Haematology</i> , 1998, 103, 1124-1128.	1.2	14
133	Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese patients with Ki-1 anaplastic large cell lymphoma: Special emphasis on the tumor response to 13-Cis retinoic acid. , 1996, 78, 1805-1812.		35
134	Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese patients with Ki-1 anaplastic large cell lymphoma: Special emphasis on the tumor response to 13-Cis retinoic acid. , 1996, 78, 1805.		3
135	Hypovolemic shock and mortality after ingestion of <i>Tripterygium wilfordii</i> hook F.: a case report. <i>International Journal of Cardiology</i> , 1995, 49, 173-177.	0.8	64